

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/atm-20-8212	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	MiR-124-3p could accelerate myogenic differentiation of ADSCs by down-regulating Cav1 to improve PFD in SD rats, which will pave the way for therapeutic delivery of miRNA targeting PFD disease.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	-
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Scholars interested in female pelvic floor dysfunction.
8	For what type of analysis or purpose?	To investigate using myogenic differentiation of adipose stem cells for the treatment of female pelvic floor dysfunction (PFD) and aimed to further study the influences of microRNA-124-3p (miR-124-3p) in the process of myogenic differentiation of adipose-derived stem cells (ADSCs) through targeting Caveolin-1 (Cav1) during PFD in Sprague Dawley (SD) rats.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: liliqun9@aliyun.com.

10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.
----	-------------------------	--